![Page 1: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/1.jpg)
Diagnostics: Novel Approaches
Institute for Atherosclerosis ResearchSkolkovo Innovative Center, Resident
![Page 2: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/2.jpg)
• activity in business and innovations since 1992• 37 trademarks, licenses, certificates• 4 DSc, 9 PhDs• +700 publications, 8 patents, 15 patent applications• 25 government-funded studies and projects• 57 contracted studies
![Page 3: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/3.jpg)
European Cardiovascular Disease Statistics 2010
![Page 4: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/4.jpg)
Cardiologist
Conclusion-high risk
- medium risk- low risk
Biochemistrycholesterol,
HDL cholesterol,LDL cholesterol,
triglycerides
Current approach
Risk Factorsage,
gender,hypertesion,
smoking,diabetes,
etc.
![Page 5: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/5.jpg)
International Task Force for Prevention of Coronary Heart Disease 2007
risk of infarction or cardiovascular death
3%low
15%intermediate
32%high
8% population
---------------------
15% population
---------------------
77% population
37% infarctions
---------------------
33% infarctions
---------------------
30% infarctions
![Page 6: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/6.jpg)
problem: no adequate methods of individual risk assessment
decision: novel highly informative markers + novel methodology
![Page 7: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/7.jpg)
Software & Hardware Complex
Risk factors &Biochemistry
Physician
Conclusion
UltrasoundGenetics *Genetics *
* Genetic diagnostics: principally novel markers (mutations in mitochondrial genome)
![Page 8: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/8.jpg)
current approach
our decision our is better
Sensitivity ~65% ~90% ~1,4-fold
Specificity ~60% ~85% ~1,4-fold
Accuracy ~60% ~85% ~1,4-fold
Resolution ~40% ~75% ~1,9-fold
![Page 9: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/9.jpg)
Company result of diagnostics * price
Progenika(Spain/USA)
reveal 1 case in 300-500 examinations $500
deCODE Genetics(USA)
reveal 1 case in 40-70 examinations $500
Our decision reveal 1 case in 4-6 examinations $200
* real incidence of predisposal to atherosclerosis, 1 case in 3-4 persons
![Page 10: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/10.jpg)
01.2007 09.2012 12.2015
basic research
clinical and epidemiologic studies
laboratory samples
prototype
verification studies
product development activities
$1.23M
~$9.7M
product optimization
![Page 11: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/11.jpg)
• investments in the project ~$4.8M
• investor’s participation in the form of a contribution to share capital and/or
contribution to the property
• sale of shares when the estimated volume of sales and/or capitalization
level is achieved
• exclusive license (for profiled investor)
![Page 12: создание апк для генодиагностики атеросклероза](https://reader033.vdocuments.us/reader033/viewer/2022060204/559f6f981a28ab05068b46cc/html5/thumbnails/12.jpg)
EXECUTIVE SUMMARY
problem: no adequate methods of individual risk assessment
decision: novel highly informative markers + novel methodology
product: diagnostic kits + hardware & software complex for data interpretation
competitive advantages: no direct analogues, innovative methodology, IP as EU patent and patent applications, unbeaten diagnostic value; quantitative estimates
market size: up to 50M potential end users in Russia; obvious perspectives for global markets